DUKE-ODYSSEY
Phase N/A
OPEN TO ACCRUAL
Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC)
EXELIXIS-XL092-002
Phase I
OPEN TO ACCRUAL
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
NRG-GU012-SAMURAI
Phase II
OPEN TO ACCRUAL
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)